SG11202110400QA - Fusion protein and use thereof - Google Patents
Fusion protein and use thereofInfo
- Publication number
- SG11202110400QA SG11202110400QA SG11202110400QA SG11202110400QA SG11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA SG 11202110400Q A SG11202110400Q A SG 11202110400QA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion protein
- fusion
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910260447.5A CN111763261B (zh) | 2019-04-02 | 2019-04-02 | 一种融合蛋白及其用途 |
PCT/CN2020/082861 WO2020200256A1 (zh) | 2019-04-02 | 2020-04-01 | 一种融合蛋白及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110400QA true SG11202110400QA (en) | 2021-10-28 |
Family
ID=72664537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110400QA SG11202110400QA (en) | 2019-04-02 | 2020-04-01 | Fusion protein and use thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220251154A1 (zh) |
EP (1) | EP3950720A4 (zh) |
JP (1) | JP2022527705A (zh) |
KR (1) | KR20210146916A (zh) |
CN (2) | CN111763261B (zh) |
AU (1) | AU2020250613A1 (zh) |
BR (1) | BR112021019570A2 (zh) |
CA (1) | CA3131075A1 (zh) |
SG (1) | SG11202110400QA (zh) |
WO (1) | WO2020200256A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220118963A (ko) * | 2021-02-19 | 2022-08-26 | (주)샤페론 | Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도 |
CN113773401B (zh) * | 2021-09-15 | 2023-06-20 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和pd-l1的重组融合蛋白及其制备和用途 |
CN118139874A (zh) * | 2021-11-01 | 2024-06-04 | 山东先声生物制药有限公司 | SIRPa突变体及其应用 |
CN116178561A (zh) * | 2021-11-26 | 2023-05-30 | 杭州尚健生物技术有限公司 | 包含SIRPα突变体的融合蛋白 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
GB8822228D0 (en) | 1988-09-21 | 1988-10-26 | Southern E M | Support-bound oligonucleotides |
EP2167531B1 (en) * | 2007-05-25 | 2012-03-21 | Novartis AG | Streptococcus pneumoniae pilus antigens |
MX2013013054A (es) * | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
CN106535914B (zh) * | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
WO2016022971A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
SG11201701189TA (en) * | 2014-08-15 | 2017-03-30 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
EP3331901A1 (en) * | 2015-08-07 | 2018-06-13 | Pieris Pharmaceuticals GmbH | Novel fusion polypeptide specific for lag-3 and pd-1 |
EP3913051A1 (en) * | 2015-08-07 | 2021-11-24 | ALX Oncology Inc. | Constructs having a sirp-alpha domain or variant thereof |
CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
EP3551661A1 (en) * | 2016-12-09 | 2019-10-16 | Alector LLC | Anti-sirp-alpha antibodies and methods of use thereof |
JP7296367B2 (ja) * | 2017-05-08 | 2023-06-22 | シャンハイ ジェイエムティー-バイオ テクノロジー カンパニー リミテッド | 二重特異性組換えタンパク質およびその応用 |
CN109517054B (zh) * | 2018-12-04 | 2022-04-08 | 江苏东抗生物医药科技有限公司 | SIRPα变体或其融合蛋白及其应用 |
CN109535263B (zh) * | 2018-12-04 | 2022-06-17 | 江苏东抗生物医药科技有限公司 | SIRPα突变体及其融合蛋白 |
-
2019
- 2019-04-02 CN CN201910260447.5A patent/CN111763261B/zh active Active
-
2020
- 2020-04-01 BR BR112021019570A patent/BR112021019570A2/pt unknown
- 2020-04-01 CN CN202080023723.7A patent/CN113631582B/zh active Active
- 2020-04-01 AU AU2020250613A patent/AU2020250613A1/en not_active Abandoned
- 2020-04-01 US US17/599,733 patent/US20220251154A1/en active Pending
- 2020-04-01 EP EP20782966.4A patent/EP3950720A4/en active Pending
- 2020-04-01 KR KR1020217030645A patent/KR20210146916A/ko not_active Application Discontinuation
- 2020-04-01 JP JP2021556959A patent/JP2022527705A/ja active Pending
- 2020-04-01 CA CA3131075A patent/CA3131075A1/en active Pending
- 2020-04-01 SG SG11202110400QA patent/SG11202110400QA/en unknown
- 2020-04-01 WO PCT/CN2020/082861 patent/WO2020200256A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021019570A2 (pt) | 2021-11-30 |
EP3950720A4 (en) | 2023-04-12 |
WO2020200256A1 (zh) | 2020-10-08 |
CN113631582B (zh) | 2024-09-06 |
AU2020250613A1 (en) | 2021-11-11 |
CN113631582A (zh) | 2021-11-09 |
KR20210146916A (ko) | 2021-12-06 |
CN111763261B (zh) | 2022-08-09 |
US20220251154A1 (en) | 2022-08-11 |
JP2022527705A (ja) | 2022-06-03 |
EP3950720A1 (en) | 2022-02-09 |
CA3131075A1 (en) | 2020-10-08 |
CN111763261A (zh) | 2020-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288373A (en) | flt3l-fc fusion proteins and methods of use | |
IL279510A (en) | Progranulin-FC polypeptide fusion proteins and their uses | |
SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
SI3565579T1 (sl) | PD1-41BBL fuzijski protein in postopki njegove uporabe | |
IL267862A (en) | SIRPalpha-41BBL conjugate protein and methods of using it | |
SG11202104912SA (en) | Fusion protein and use thereof | |
EP3960756A4 (en) | FLAGELLIN FUSION PROTEIN AND ITS USE | |
SG11202110400QA (en) | Fusion protein and use thereof | |
EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF | |
IL284679A (en) | Multifunctional chimeric proteins and their use | |
IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
IL275248A (en) | Fusion protein of a therapeutic enzyme with a new structure and its use | |
EP3858866A4 (en) | GLP1-FC-FUSION PROTEIN AND CONJUGATE THEREOF | |
ZA202000595B (en) | Novel therapeutic enzyme fusion protein and use thereof | |
IL279057A (en) | Antimicrobial fusion proteins containing endolysin and their uses | |
GB202201003D0 (en) | Fusion polypeptide and use thereof | |
GB2600592B (en) | Polypeptide and use thereof | |
ZA202100092B (en) | Modified cas9 protein and use thereof | |
ZA202102533B (en) | Fusion protein | |
IL290715A (en) | nkg2d fusion proteins and their use | |
EP3816181A4 (en) | IMPROVED FVIII FUSION PROTEIN AND ITS USE | |
IL286799A (en) | Consolidated structures and their uses | |
GB202201004D0 (en) | Reconbinant fusion polypeptide and use thereof | |
EP3947418C0 (en) | PEPTIDES AND THEIR USE |